Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling

Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain.